Advancing the Prevention and Treatment of Heart Failure

Exploring New Paradigms

  • Sunday, September 29, 2024
  • 7:00 am - 8:00 am ET
  • Room: Triumph E
  • Signia Hotel Atlanta | Atlanta, Georgia
  • CME/CPE
  • Hybrid
Overview

This satellite symposium, held in conjunction with the 2024 Heart Failure Society of America (HFSA) Annual Meeting, has been indefinitely postponed due to the current forecast for the Atlanta, Georgia area. This cancellation includes the virtual program.

We will reach out to all registered attendees to confirm the new event date as soon as possible. We appreciate your patience and understanding and we look forward to seeing you at another Medscape event in the near future.

Speakers
Speaker Image
Javed Butler, MD, MBA, MPH
MODERATOR

President of the Baylor Scott and White Research Institute
Maxwell A. and Gayle H. Clampitt Endowed Chair
Dallas, Texas
Distinguished Professor of Medicine
University of Mississippi
Jackson, Mississippi

Speaker Image
Scott D. Solomon, MD
PANELIST

Edward D. Frohlich Distinguished Chair

Professor of Medicine

Harvard Medical School

Brigham and Women's Hospital

Boston, Massachusetts​

Speaker Image
Martha Gulati, MD, MS
PANELIST

Professor of Medicine

Director, Preventive Cardiology

Associate Director, Barbra Streisand Women’s Heart Center

Anita D. Friedman Chair in Cardiovascular Medicine & Research

Smidt Heart Institute at Cedars Sinai Medical Center

Los Angeles, California

Agenda

6:30 am

Meal and Registration

7:00 am

Welcome and Introductions

State of the State – Preventing and Treating HF Today

Focus on MRAs for HF – Past, Present, and Future

Implementing the Latest Guideline Recommendations for HF Prevention and Treatment

Conclusion and Q&A

159 Northside Dr NW, Room: Triumph E, Atlanta, Georgia, 30313
Get Directions
Program Information
Accreditation Statement

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Accreditation logos
Accreditation logos
For Physicians

Medscape, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Pharmacists

Medscape designates this continuing education activity for 1.0 contact hour(s) (0.100 CEUs) (Universal Activity Number: JA0007105-0000-24-224-L01-P).

Learning Objectives

Upon completion of this activity, participants will:

Have increased knowledge regarding the:

  • New therapeutic options to prevent/treat HF
  • Latest guideline recommendations for HF prevention and treatment
  • Role of mineralocorticoid receptor antagonists (MRAs) in the prevention and treatment of HF
  • Mechanism of action of MRAs, including key differentiators between nonsteroidal MRAs (nsMRAs) and steroidal MRAs (sMRAs)
  • Evolving clinical trial evidence for nsMRA in the setting of HF
Goal Statement

The goal of this activity is for learners to be better able to evaluate emerging treatment strategies for the treatment of HF.

Target Audience

This activity is intended for cardiologists, primary care physicians, nephrologists, nurses, and pharmacists.

Supported by an independent educational grant from Bayer.

This Satellite Symposium is presented through a collaboration between Medscape and the Heart Failure Society of America. The program topic, learning objectives, and faculty have been reviewed and approved by the ASM Satellite Review Committee. Satellite sessions are not a part of the scientific program as planned and executed by the HFSA Program Committee.